Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Flow-Therapy for Cheyne-Stokes-Respiration in Heart Failure
NCT03102827Phase 3Terminated
- Sponsor
- Heart and Diabetes Center North Rhine-Westphalia
- Start
- Feb 2017
- Primary completion
- Mar 2018
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxygen in Cheyne-Stokes respiration (CSR) (2 arms), sponsored by Heart and Diabetes Center North Rhine-Westphalia. Primary endpoint: Reduction of hypoxemic burden at Day 3. Started Feb 2017; status: terminated.
02
Drugs
oxygen
03
Conditions
Cheyne-Stokes respiration (CSR)
Beyond the preview
Go deeper on NCT03102827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102827.